Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07412496 | A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | PHASE2 | NOT YET_RECRUITING | 123 | — | — | Apr 1, 2026 | Feb 1, 2027 | Feb 17, 2026 | - | — |
Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain
| Arm | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | EXPERIMENTAL | BL1332 low dose ocular drop used 5x daily |
| Topical Ocular BL1332 high dose | EXPERIMENTAL | BL1332 high dose ocular drop used 5x daily |
| BL1332 ophthalmic vehicle | PLACEBO_COMPARATOR | BL1332 vehicle ocular drop used 5x daily |
| Name | Type | Description |
|---|---|---|
| Topical Ocular BL1332 low dose | DRUG | Administered 5 times a day |
| Topical Ocular BL1332 high dose | DRUG | Administered 5 times a day |
| BL1332 Vehicle ophthalmic vehicle | DRUG | Administered 5 times a day |
Inclusion Criteria: 1. Male or female 18 to 58 years of age, inclusive. 2. Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion. 3. Provide written informed consent (signed and dated informed consent form \[ICF\]) using the Institutional Review Bo...